Review
Oncology
Lori J. Wirth, Cosimo Durante, Duncan J. Topliss, Eric Winquist, Eyal Robenshtok, Hiroyuki Iwasaki, Markus Luster, Rossella Elisei, Sophie Leboulleux, Makoto Tahara
Summary: This review discusses the optimization of lenvatinib treatment for RR-DTC. Starting lenvatinib treatment earlier in the course of the disease, with a lower disease burden, yields better outcomes for patients. A starting dose of 24 mg/day, with dose modifications as needed, provides better treatment efficacy. Appropriate supportive care for lenvatinib-related toxicities is also crucial.
Article
Oncology
Freba Ahmaddy, Caroline Burgard, Leonie Beyer, Viktoria Florentine Koehler, Peter Bartenstein, Matthias P. Fabritius, Thomas Geyer, Vera Wenter, Harun Ilhan, Christine Spitzweg, Andrei Todica
Summary: The study aimed to assess the role of F-18-FDG-PET in monitoring functional tumor response and found that F-18-FDG-PET outperforms CT in evaluating tumor response in patients with advanced radioiodine refractory DTC treated with Lenvatinib, which appears to be correlated with clinical outcomes.
Review
Oncology
Urbano Anido Herranz
Summary: Thyroid cancer is a common endocrine tumor, and currently radioactive iodine and multikinase inhibitors are the main treatment options. This review explores the potential combination of MKIs/lenvatinib with RAI and evaluates its applicability in special situations.
Review
Oncology
Javier Martinez-Trufero
Summary: Lenvatinib is highly active in radioiodine-refractory differentiated thyroid cancer (RR-DTC) and has become an important therapeutic tool. However, treating RR-DTC patients with renal or hepatic impairment is challenging. Strict adherence to the recommended use and dose adjustments of lenvatinib, as well as close clinical and blood monitoring, is essential for optimizing treatment outcomes.
Article
Medicine, General & Internal
Maaike Dotinga, Dennis Vriens, Floris H. P. van Velden, Mette K. K. Stam, Jan W. T. Heemskerk, Petra Dibbets-Schneider, Martin Pool, Daphne D. D. Rietbergen, Lioe-Fee de Geus-Oei, Ellen Kapiteijn
Summary: The management of RAI-refractory DTC patients is challenging, and current standard-of-care systemic therapy with lenvatinib has frequent toxicities. This study aims to investigate the optimal duration and efficacy of lenvatinib treatment and the feasibility and safety of subsequent I-131 therapy. Identifying patients who redifferentiate after lenvatinib therapy is crucial for improving the quality of life and reducing toxicity.
Article
Oncology
Luca Giovanella, Desiree' Deandreis, Alexis Vrachimis, Alfredo Campenni, Petra Petranovic Ovcaricek
Summary: Molecular imaging plays a crucial role in the evaluation and management of thyroid cancer, contributing to the optimization of treatment decisions and the improvement of risk stratification models. Different molecular imaging techniques can be used to detect various types of thyroid cancer, and new theragnostic approaches offer promising prospects for treatment.
Article
Oncology
Costanza Chiapponi, Milan J. M. Hartmann, Matthias Schmidt, Michael Faust, Anne M. Schultheis, Christiane J. Bruns, Hakan Alakus
Summary: The majority of patients with differentiated thyroid cancer can be effectively treated with thyroidectomy and radioiodine therapy. However, a small percentage of patients may become unresponsive to radioiodine treatment, requiring repetitive surgery as the only curative option. Despite surgery and external beam radiation, cure for cervical relapse of radioiodine refractory FTC is rare, highlighting the need for early biological markers and systemic treatments for these patients.
Article
Oncology
Makoto Tahara, Naomi Kiyota, Ana O. Hoff, Corin Badiu, Taofeek K. Owonikoko, Corina E. Dutcus, Takuya Suzuki, Min Ren, Lori J. Wirth
Summary: This study investigated the impact of lung metastases on the overall survival of patients with radioiodine-refractory differentiated thyroid cancer, and found that lenvatinib treatment prolonged the OS in patients with lung metastases of >= 1.0 cm. Multivariate analysis confirmed the significant clinical benefit of lenvatinib in this subgroup of patients.
EUROPEAN JOURNAL OF CANCER
(2021)
Article
Oncology
Chiaki Suzuki, Naomi Kiyota, Yoshinori Imamura, Hideaki Goto, Hirotaka Suto, Naoko Chayahara, Masanori Toyoda, Yasuhiro Ito, Akihiro Miya, Akira Miyauchi, Masanori Teshima, Naoki Otsuki, Ken-ichi Nibu, Hironobu Minami
Summary: The study found that long-term responders had smaller post-treatment tumor burden compared to non-long-term responders. There was a strong linear correlation between pre- and post-treatment tumor burden. The results suggested a potential cut-off value for baseline tumor burden related to long-term prognosis among patients treated with lenvatinib.
FRONTIERS IN ONCOLOGY
(2021)
Article
Endocrinology & Metabolism
Jaume Capdevila, Desiree' Deandreis, Cosimo Durante, Sophie Leboulleux, Markus Luster, Romana Netea-Maier, Kate Newbold, Susanne Singer, Gerasimos P. Sykiotis, Beate Bartes, Kate Farnell, Laura Deborah Locati
Summary: It is essential to provide guidance for the management of RAI-R DTC patients with systemic therapies, and especially lenvatinib, since compliance and adherence to treatment are fundamental to achieve the best outcomes. The therapeutic landscape in RAI-R DTC is evolving, with new targeted therapies, immunotherapy, etc., lenvatinib is expected to remain a first-line treatment and mainstay of therapy for several years in the vast majority of patients and settings.
EUROPEAN THYROID JOURNAL
(2023)
Article
Endocrinology & Metabolism
C. Saie, J. Wassermann, E. Mathy, N. Chereau, L. Leenhardt, S. Tezenas du Montcel, C. Buffet
Summary: The study found that different age cutoffs have some impact on the survival and disease progression of RAIR-DTC patients, but age 65 is not a significant predictive factor for survival. Cutoffs at 45 and 75 years old were predictive for overall survival but not progression-free survival.
EUROPEAN JOURNAL OF ENDOCRINOLOGY
(2021)
Article
Oncology
He-Jiun Jiang, Yen-Hsiang Chang, Yen-Hao Chen, Che-Wei Wu, Pei-Wen Wang, Pi-Jung Hsiao
Summary: The study found that low-dose lenvatinib treatment was well tolerated and effective in patients with radioiodine-refractory differentiated thyroid carcinoma (RRDTC), achieving good disease control rates and treatment outcomes.
CANCER MANAGEMENT AND RESEARCH
(2021)
Article
Endocrinology & Metabolism
Chao Meng, Juanjuan Song, Wen Long, Zhuanzhuan Mu, Yuqing Sun, Jun Liang, Yansong Lin
Summary: A convenient nomogram model was developed to predict radioiodine refractory differentiated thyroid cancer. The progression of this cancer can be further stratified as rapidly or slowly progressive based on biochemical markers and age.
FRONTIERS IN ENDOCRINOLOGY
(2023)
Article
Oncology
Laura Boucai, Mahesh Saqcena, Fengshen Kuo, Ravinder K. Grewal, Nicholas Socci, Jeffrey A. Knauf, Gnana P. Krishnamoorthy, Mabel Ryder, Alan L. Ho, Ronald A. Ghossein, Luc G. T. Morris, Venkatraman Seshan, James A. Fagin
Summary: The determinants of response or resistance to radio-iodine (RAI) are unknown. The study aimed to identify genomic and transcriptomic factors associated with structural responses to RAI treatment of metastatic thyroid cancer. It was found that high MAPK pathway output was associated with RAI refractoriness. ER tumors have a lower MAPK output and higher TDS than NR, whereas NR have a high frequency of BRAFV600E and 1q-gain. Molecular profiling of thyroid cancers may help predict response to RAI therapy.
CLINICAL CANCER RESEARCH
(2023)
Article
Medicine, General & Internal
Xian Cheng, Shichen Xu, Yun Zhu, Jing Wu, Jiandong Bao, Huixin Yu, Li Zhang
Summary: The study found that elevated preoperative thyroglobulin (pre-Tg) levels are associated with radioiodine refractory (RAIR) in patients with differentiated thyroid cancer (DTC), serving as an independent predictor. This marker can guide more precise treatment strategies and follow-up monitoring for RAIR-DTC patients.
EUROPEAN JOURNAL OF CLINICAL INVESTIGATION
(2022)
